Precision BioSciences (DTIL) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 48.0% versus a loss of 39.9%. Precision BioSciences is the larger company by market cap ($282.5 million vs $269.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | KYTX |
|---|---|---|
| Share price | $7.40 | $4.26 |
| Market cap | $282.46M | $269.33M |
| 1-day change | +7.09% | -2.52% |
| YTD return | +77.88% | -54.68% |
| 1-year return | +48.00% | -39.92% |
| 5-year return | -97.23% | — |
| P/E ratio (TTM) | 29.60 | — |
| EPS (TTM) | $0.25 | $-2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $34.26M | — |
| Revenue growth (YoY) | -50.12% | — |
| Net income (latest FY) | $-45.72M | $-161.31M |
| Operating margin | -152.19% | — |
| Net margin | -133.45% | — |
| 52-week high | $11.29 | $13.67 |
| 52-week low | $3.53 | $4.18 |
| Distance from 52-week high | -34.46% | -68.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +297.30% | +613.62% |
| Average volume | 319.79K | 867.28K |
| Shares outstanding | 38.17M | 63.22M |
| Employees | 69 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed KYTX by 87.9 percentage points over the past year.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees
DTIL vs KYTX FAQ
Which is bigger, Precision BioSciences or Kyverna Therapeutics?
Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $269.33M for Kyverna Therapeutics (KYTX).
Which stock has performed better over the past year, DTIL or KYTX?
DTIL returned +48.00% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.